Haya Therapeutics

News

Pathos AI's big $365m Series D, and other bio financings

Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.

News

Samir Ounzain, CEO and co-founder of Haya Therapeutics

Lilly to hunt non-coding DNA for obesity drugs in $1bn deal

Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.

News

Servier snaps up cancer biotech Day One in $2.5bn deal

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks